公开(公告)号：US20240352124A1

公开(公告)日：2024-10-24

申请号：US18512432

申请日：2023-11-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Eric Smith ,  Nicholas J. Papadopoulos

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2809 ,  C07K16/2887 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/92 ,  Y02A50/30

Abstract: The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

公开(公告)号：US20240343798A1

公开(公告)日：2024-10-17

申请号：US18682489

申请日：2022-08-09

Applicant: GV20 Therapeutics LLC ,  Shanghai XunBaiHui Biotechnology Co., LTD.

Inventor： Tengfei Xiao ,  Xihao Hu ,  Xiaole Shirley Liu

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61P35/04 ,  G01N33/5023 ,  G01N33/57492 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N2333/70503

Abstract: The present invention provides methods and compositions for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

公开(公告)号：US20240342278A1

公开(公告)日：2024-10-17

申请号：US18523203

申请日：2023-11-29

Applicant: Omeros Corporation

Inventor： W. Jason Cummings ,  Gregory A. Demopulos ,  Thomas A. Dudler ,  Larry W. Tjoelker ,  Christi L. Wood ,  Munehisa Yabuki

IPC: A61K39/395 ,  B82Y25/00 ,  C01F17/206 ,  C07K16/40 ,  C09K11/77 ,  C12N9/64 ,  H01F1/00 ,  A61K39/00

CPC classification number: A61K39/3955 ,  B82Y25/00 ,  C01F17/206 ,  C07K16/40 ,  C09K11/77 ,  C09K11/7728 ,  C12N9/6424 ,  C12Y304/21104 ,  H01F1/0054 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C01P2002/54 ,  C01P2002/84 ,  C01P2004/64 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

公开(公告)号：US20240336682A1

公开(公告)日：2024-10-10

申请号：US18293500

申请日：2022-07-27

Applicant: SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.

Inventor： Chong ZHOU ,  Liusong YIN ,  Xiaoling JIANG

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/569 ,  C07K2317/734 ,  C07K2317/76

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates the tumor microenvironment. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

公开(公告)号：US20240327536A1

公开(公告)日：2024-10-03

申请号：US18590267

申请日：2024-02-28

Applicant: Genentech, Inc.

Inventor： David LEPPERT ,  Anne-Marie LI-KWAI-CHEUNG ,  Michele LIBONATI ,  Donna MASTERMAN ,  Jean-Paul PFEFEN ,  Craig SMITH ,  Algirdas Jonas Kakarieka WEISSKOPF ,  Jiameng ZHANG ,  Peter S. CHIN ,  Hideki GARREN

IPC: C07K16/28 ,  A61K38/00 ,  A61K39/00 ,  A61P37/06

CPC classification number: C07K16/2887 ,  A61P37/06 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufac-ture with instructions for such use.

公开(公告)号：US20240301062A1

公开(公告)日：2024-09-12

申请号：US18620439

申请日：2024-03-28

Applicant: BeiGene Switzerland GmbH

Inventor： Liu XUE ,  Ming LEI ,  Yao DING ,  Ruyue JI ,  Yun CHEN

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61K47/22 ,  A61K47/26 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734

Abstract: The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.

公开(公告)号：US12077597B2

公开(公告)日：2024-09-03

申请号：US17534707

申请日：2021-11-24

Applicant: INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH

Inventor： Claudine Vermot-Desroches ,  Hélène Rouquette ,  Benoît Milcent

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734

Abstract: Novels antibodies, preferably monoclonal antibodies, or antigen-binding fragments thereof, said antibody or fragment thereof specifically binding to CD5. These antibodies may be used as a medicament, especially in the treatment of diseases in immunomodulation, inflammation, virology, infectiology, autoimmunity and oncology domains. Immune cells and/or cancer cells targeted by the invention are expressing CD5 antigen. These antibodies may be in particular chimeric or humanized. The invention also relates to pharmaceutical compositions, such as immunomodulator, anti-cancerous and anti-infectious compositions, containing such an antibody or antigen-binding fragment and methods of use of these, either for laboratory work, in drug manufacturing, such as in cell therapy cells production, or for medical treatment.

公开(公告)号：US20240279273A1

公开(公告)日：2024-08-22

申请号：US18462624

申请日：2023-09-07

Applicant: Gliknik Inc.

Inventor： David S. BLOCK ,  Emmanuel Y. MERIGEON ,  Henrik OLSEN

IPC: C07K1/22 ,  C07K1/18 ,  C07K16/18

CPC classification number: C07K1/22 ,  C07K1/18 ,  C07K16/18 ,  C07K2317/734

Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.

公开(公告)号：US20240270863A1

公开(公告)日：2024-08-15

申请号：US18597659

申请日：2024-03-06

Applicant: TG Therapeutics, Inc. ,  Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Inventor： George Costas Avgerinos ,  Patrick Michael Hossler ,  Jill A. Myers ,  Yune Z. Kunes

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

公开(公告)号：US12060585B2

公开(公告)日：2024-08-13

申请号：US17302514

申请日：2021-05-05

Applicant: PRECIGEN, INC.

Inventor： Rutul Shah ,  Peter Emtage ,  Ramya Yarlagadda

IPC: C12N9/12 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C07K16/32

CPC classification number: C12N9/12 ,  A61K35/17 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/70592 ,  C07K14/70596 ,  C07K14/71 ,  C07K16/2887 ,  C07K16/32 ,  C12Y207/10001 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33

Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.